At the Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, multiple sessions aimed to provide fresh perspectives on the always challenging treatment of cancer, with a strong focus on innovative strategies.
Researchers at Queen’s University of Belfast and collaborators have developed a DNA vaccine against high-grade serous ovarian cancer. The vaccine encodes PRAME, which the researchers found to be upregulated in several cohorts of patients with the malignancy.
Medicovestor Inc.’s Adobind MC-001 has been awarded orphan drug designation by the FDA for the treatment of pancreatic cancer. Adobind MC-001 is a chemoimmunotherapy antibody-drug conjugate that integrates proprietary enhancements to antibody structure, payload delivery and tumor engagement.
Naya Therapeutics Inc. is expanding its hepatocellular carcinoma pipeline with the addition of NY-700, a first-in-class GPC3-targeted Astatine-211 (211At) α radioimmunotherapy aiming to address residual disease, micro-metastasis and post-immunotherapy failures.
Sunrock Biopharma SL and Shanghai Escugen Biotechnology Co. Ltd. have joined forces in a strategic partnership to codevelop SRB-123, a first-in-class antibody-drug conjugate (ADC) targeting C-C motif chemokine receptor 9 (CCR9), a tumor-associated antigen overexpressed in multiple solid tumors, including pancreatic, ovarian and lung cancer.
Researchers at the Olivia Newton-John Cancer Research Institute and collaborators have developed a new anti-HER2 monoclonal antibody, mAb104, which targets a conformationally exposed, tumor-specific epitope in domain II of the HER2 protein.
Myrio Therapeutics Pty Ltd. is set to advance lead product PHOX2B PC-CAR T (PHOX2B peptide-centric chimeric antigen receptor autologous T cells) into clinical trials for relapsed neuroblastoma following IND clearance by the FDA. The first patient will be enrolled around mid-year.
Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide. Recent advancements in immunotherapy have demonstrated the potential of targeting immune checkpoints and co-inhibitory pathways to enhance antitumor responses.
Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by the accumulation of immature myeloid cells. Current treatments often fail to achieve durable remission, underscoring the need for innovative therapeutic approaches. CD97 is a cell surface protein with broad, increased expression on AML cells compared to normal blood stem and progenitor cells. Moreover, CD97 overexpression in AML patients has been associated with poor survival, thus emerging as a potential therapeutic target.
RSS
